Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...
Investor's Business Daily on MSN6h
Is Moderna Stock A Sell As RFK Jr. Reportedly Mulls A Massive Funding Pull?
Moderna stock is under pressure, again, as Robert F. Kennedy Jr. reportedly mulls pulling the company's federal funding to ...
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
Moderna initiated with a Neutral at Citi
Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...
White House withdraws vaccine critic Weldon for CDC director
WASHINGTON (Reuters) - The White House withdrew President Donald Trump’s nomination of former Republican congressman and vaccine critic Dave Weldon to serve as director of the U.S. Centers for Disease ...